XON Key Stats
- ZIOPHARM Reports Positive Interim Results in Patients With Advanced Melanoma From Ongoing Phase 1/2 Study of Ad-RTS-IL-12 noodls Dec 7
- ZIOPHARM Announces Unanimous Recombinant DNA Advisory Committee (RAC) Approval for Phase 1 Study of Ad-RTS-IL-12 in Subjects With Recurrent or Progressive Glioblastoma noodls Dec 6
- ZIOPHARM Oncology (ZIOP) Receives NIH RAC Approval for Ad-RTS-IL-12 Phase 1 Street Insider Dec 6
- AQUABOUNTY CLEARED TO PRODUCE SALMON EGGS IN CANADA FOR COMMERCIAL PURPOSES (PDF) noodls Nov 25
- In Insider Trading, Purchases by GlaxoSmithKline and Noted Biotech Investor Randal Kirk Nov 25
- AquaBounty Cleared To Produce Salmon Eggs In Canada For Commercial Purposes CNW Group Nov 25
- Intrexon Appoints Executives to Expand European and Asian Markets, Accelerate Technology Platform Development noodls Nov 18
- 4 Stocks Rising on Unusual Volume Nov 18
- Intrexon Corporation (XON) in Focus: Stock Jumps 8.6% - Tale of the Tape Zacks Nov 18
- ZIOPHARM Oncology (ZIOP), Intrexon (XON) Update on RTS in hMSCs Street Insider Oct 22
XON Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Intrexon Corp is up N/A over the last year vs S&P 500 Total Return up 29.19%, ZIOPHARM Oncology down 8.56%, and Synthetic Biologics down 23.35%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for XON
Pro Report PDF for XON
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download XON Pro Report PDF
Pro Strategies Featuring XON
Did Intrexon Corp make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Intrexon Corp is a synthetic biology company that designs, builds and regulates gene programs using its proprietary and complementary technologies.